ATLANTA, GA, Lucid Scientific has announced the completion of a $3 million Series Seed financing
Lucid Scientific, the biotechnology tools company that develops and manufactures RESIPHER, announced the completion of a $3 million Series Seed financing led by Dynamk Capital. Additional participants include Lucid's original investor base and the Georgia Research Alliance's Venture Fund, bringing Lucid's total funding to date to approximately $4.5 million. Proceeds from this round will help the company aggressively expand production, sales and marketing, as well as broaden product development. Dynamk Capital Managing Partner Dr. Gustavo Mahler will join Lucid's Board of Directors.
Lucid Scientific (lucidsci.com) is a biotechnology tools company working to accelerate drug discovery and basic biological research by providing systems for real-time cellular analysis. Originally developed at MIT, Lucid's patented RESIPHER system monitors cellular metabolism via non-invasive optical sensors, streaming information to researchers in real-time via a collaborative web platform. The information provided by Lucid's systems saves time and enhances value to researchers performing millions of experiments annually. Headquartered in Atlanta, GA at the Advanced Technology Development Center (ATDC), Lucid is supported by public and private sources including Dynamk Capital and the GRA Venture Fund. For more information, visit lucidsci.com.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about